Hypomethylation-associated up-regulation of TCF3 expression and recurrence in stage II and III colorectal cancer

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Li, Chunxiang ^a   Cai, Sanjun ^b   Wang, Xishan ^a,c   Jiang, Zheng ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c Biopharmaceutical Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR 7 LIKE 1; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; TCF3 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOLECULAR DYNAMICS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TCF3 GENE; UPREGULATION; COLORECTAL TUMOR; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC;

EID: 84910676507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112005     Document Type: Article

References (36)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR, et al. (2005) Colorectal cancer. Lancet 365:153-165.
2. Cserni G (2003) Nodal staging of colorectal carcinomas and sentinel nodes. J Clin Pathol 56:327-335.
3. Chatla C, Jhala NC, Katkoori VR, Alexander D, Meleth S, et al. (2005) Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark 1:241-50.
4. Murre C, McCaw PS, Baltimore D (1989) A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56:777-783.
5. Chakraborty T, Brennan TJ, Li L, Edmondson D, Olson EN (1991) Inefficient homooligomerization contributes to the dependence of myogenin on E2A products for efficient DNA binding. Mol Cell Biol 11:3633-3641.
6. Lassar AB, Buskin JN, Lockshon D, Davis RL, Apone S, et al. (1989) MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell 58:823-831.
7. Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, et al. (1989) Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58:537-544.
8. Shen CP, Kadesch T (1995) B-cell-specific DNA binding by an E47 homodimer. Mol Cell Biol 15:4518-4524.
9. Kijanka GS, Hector S, Kay EW, Murray F, Cummins R, et al. (2010) Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut 59(1):69-78.
10. Asirvatham AJ, Carey JP, Chaudhary J (2007) ID1-, ID2-, and ID3-regulated gene expression in E2A positive or negative prostate cancer cells. Prostate 67:1411-1420.
11. Patel D, Chaudhary J (2012) Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis. Biochem Biophys Res Commun 422(1):146-51.
12. Sagara N, Katoh M (2000) Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation. Cancer Res 60:5959-5962.
13. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, et al. (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66:2725-2731.
14. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, et al. (2001) A new role for E12/E47 in the repression of E-cadherin expression and epithelialmesenchymal transitions. J Biol Chem 276:27424-27431.
15. Fukuyama R, Niculaita R, Ng KP, Obusez E, Sanchez J, et al. (2008) Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene 27:6044-6055.
16. Hata F, Nishimori H, Yasoshima T, Tanaka H, Ohno K, et al. (2004) Profiling analysis of differential gene expression between hematogenous and peritoneal metastatic sublines ofhuman pancreatic cancer using a DNA chip. J Exp Clin Cancer Res 23(3):513-20.
17. Zhao H, Huang A, Li P, Quan Y, Feng B, et al. (2013) E2A suppresses invasion and migration by targeting YAP in colorectal cancer cells. J Transl Med 11:317.
18. Jiang Z, Xu Y, Cai S. (2011) Down-regulated GAS1 expression correlates with recurrence in stage II and III colorectal cancer. Hum Pathol 42(3):361-8.
19. Oliver JA, Ortiz R, Melguizo C, Alvarez PJ, Gómez-Millán J, et al. (2014) Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma. BMC Cancer 14:511.
20. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, et al. (2009) Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69:1343-1349.
21. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, et al. (1996) Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 59:3-10.
22. Molenaar M, Van De Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, et al. (1996) XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86:391-399.
23. Papkoff J, Rubinfeld B, Schryver B, Polakis P (1996) Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Mol Cell Biol 16:2128-2134.
24. Porfiri E, Rubinfeld B, Albert I, Hovanes K, Waterman M, et al. (1997) Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. Oncogene 15:2833-2839.
25. Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, et al. (2002) Role of betacatenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 160:1229-1238.
26. Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, et al. (2003) Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63:2913-2922.
27. Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153:333-339.
28. Mareel M, Boterberg T, Noë V, Van Hoorde L, Vermeulen S, et al. (1997) E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 173:271-274.
29. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, et al. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845-3852.
30. Berx G, Becker KF, Höfler H, Van Roy F (1998) Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12:226-237.
31. Nieto MA (2002) The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3:155-166.
32. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454.
33. Laux H, Tomer R, Mader MT, Smida J, Budczies J, et al. (2004) Tumorassociated E-cadherin mutations do not induce Wnt target gene expression, but affect E-cadherin repressors. Lab Invest 84:1372-1386.
34. NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450.
35. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol 17:1349-1355.
36. Macdonald JS (1999) Adjuvant therapy of colon cancer. CA Cancer J Clin 49:202-219.